Community-randomized trial of enhanced DOTS for tuberculosis control in Rio de Janeiro, Brazil

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 2, 2010, Pages 203-209

  Cavalcante, S C ^a,b   Durovni, B ^a,c   Barnes, G L ^d   Souza, F B A ^a,e   Silva, R F ^a   Barroso, P F ^c   Mohan, C I ^d   Miller, A ^d   Golub, J E ^d   Chaisson, R E ^d  

^a Municipal Health Secretariat   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

Author keywords

DOTS; Household contacts; Latent TB infection treatment; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; BACTERIOLOGY; BRAZIL; CHEMOPROPHYLAXIS; FEMALE; HEALTH CARE POLICY; HEALTH PROGRAM; HOUSEHOLD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCREENING; SELF CARE; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; VACCINATION;

ADULT; ANTITUBERCULAR AGENTS; BRAZIL; CONTACT TRACING; DIRECTLY OBSERVED THERAPY; FAMILY CHARACTERISTICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASS SCREENING; TUBERCULOSIS; URBAN POPULATION;

EID: 77049117791     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Enarson D, Rieder H, Arnadottir T, Trébucq A. Management of tuberculosis. A guide for low income countries. 5th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000.
2. World Health Organization. Framework for effective tuberculosis control. WHO report 1994. WHO/TB/94.179. Geneva, Switzerland: WHO, 1994. http://whqlibdoc.who.int/hq/1994/WHO-TB-94.179.pdf Accessed November 2009.
3. De Cock K M, Chaisson R E. Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999; 3: 457-464.
4. Kenyon T A, Mwasekaga M J, Huebner R, et al. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana. Int J Tuberc Lung Dis 1999; 3: 4-11.
5. Morrison J, Pai M, Hopewell P C. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8: 359-368.
6. Comstock G W, O'Brien R J. Tuberculosis. In: Evans A S, Brachman P S, Bacterial infections of humans: epidemiology and control. 2nd ed. New York, NY, USA: Plenum, 1991.
7. Small P M, Hopewell P C, Singh S P, et al. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994; 330: 1703-1709.
8. Alland D, Kalkut, G E, Moss A R, et al. Transmission of tuberculosis in New York City. An analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 1994; 330: 1711-1716.
9. Cohn D L, O'Brien R J. The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. Int J Tuberc Lung Dis 1998; 2: 16-26.
10. Blower S M, Small P M, Hopewell P C. Control strategies for tuberculosis epidemics: new models for old problems. Science 1996; 273: 497-500.
11. Chaulk C P, Friedman M, Dunning R. Modeling the epidemiology and economics of directly observed therapy in Baltimore. Int J Tuberc Lung Dis 2000; 4: 201-207.
12. Ministério da Saúde, Fundação Nacional de Saúde. Guia de vigilância epidemiológica. Brasília DF, Brazil: Ministério da Saúde, 2002. [Portuguese]
13. Cavalcante S C, Soares E C C, Rocha M S, et al. A implantaçäo da estratégia DOTS na cidade do Rio de Janeiro. Pulmão RJ 2003; 12: 51-56. [Portuguese]
14. Soares E C C, Pacheco, A G F, Mello F C Q, et al. Improvements in treatment success rates with directly observed therapy in Rio de Janeiro City. Int J Tuberc Lung Dis 2006; 10: 690-695.
15. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006; 173: 922-926.
16. American Thoracic Society. Centers for Disease Control and Prevention. Targeted tuberculin skin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-S247.
17. Chaulk P C, Moore-Rice K, Rizzo R, Chaisson R E. Eleven years of community-based directly observed therapy for tuberculois. JAMA 1995; 274: 945-951.
18. Weiss S E, Slocum P C, Blais F X, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179-1184.
19. Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333: 229-333.
20. Newell J N, Baral S C, Pande S B, Bam D S, Malla P. Family-member DOTS and community DOTS for tuberculosis control in Nepal: cluster-randomised controlled trial. Lancet 2006; 367: 903-909.
21. Thiam S, LeFevre A M, Hane F, et al. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting. JAMA 2007; 297: 380-386.
22. Suârez P G, Watt C J, Alarcón E, et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis 2001; 184: 473-478.
23. Dowdy D W, Chaisson R E. The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull World Health Organ 2009; 87: 296-304.
24. Teixeira L, Perkins M D, Johnson J L, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 321-328.
25. Carvalho A C C, Kritski A L, De Riemer K. Tuberculin skin testing among BCG-vaccinated children who are household contacts. Int J Tuberc Lung Dis 2001; 5: 297.
26. Carvalho A C C, De Riemer K, Nunes Z B, et al. Transmission of Mycobacterium tuberculosis to contacts of HIV-infected tuberculosis patients. Am J Respir Crit Care Med 2001; 164: 2166-2171.
27. Nunn P, Mungai M, Nyamwaya J, et al. The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis. Tubercle Lung Dis 1994; 75: 25-32.
28. Guwatudde D, Nakakeeto M, Jones-Lopez E C, et al. Tuberculosis in household contacts of infectious cases in Kampala, Uganda. Am J Epidemiol 2003; 158: 887-898.
29. Cailleaux-Cezar M, Melo A D, Xavier G M, et al. Tuberculosis incidence among contacts of active pulmonary tuberculosis. Int J Tuberc Lung Dis 2009; 13: 190-195.
30. Godfrey-Faussett P, Sonnenberg P, Shearer S C, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000; 356: 1066-1071.